A Phase 1, Open-Label, Multiple-Ascending Dose Study Of The Safety And Tolerability Of CTX-471 In Patients With Inadequate Responses To PD-1/PD-L1 Checkpoint Inhibitors In Metastatic Or Locally Advanced Malignancies